8-K: Nordicus Partners Corporation Acquires Bio-Convert ApS in All-Stock Transaction

Nordicus Partners Corporation has acquired Bio-Convert ApS, a clinical-stage biopharmaceutical company, in an all-stock transaction, issuing 12 million restricted shares of its common stock.

Summary

• Nordicus Partners Corporation acquired Bio-Convert ApS by issuing 12,000,000 restricted shares of its common stock to the sellers.
• The acquisition was completed on November 12, 2024, with the agreement signed on November 11, 2024.
• Bio-Convert is a Danish biopharmaceutical company focused on developing treatments for oral leukoplakia and preventing oral cancer.
• Nordicus Partners Corporation specializes in assisting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market.
• The transaction involved Nordicus acquiring 100% of Bio-Convert's outstanding shares, which totaled 595,400 shares.

Sentiment

Score: 7

Explanation: The document indicates a positive strategic move for Nordicus with the acquisition of Bio-Convert, but the risks associated with clinical trials and market acceptance temper the overall sentiment. The all-stock deal also introduces some uncertainty.

Positives

• Nordicus Partners Corporation has expanded its portfolio by acquiring a company focused on a specific medical need.
• The acquisition of Bio-Convert provides Nordicus with a new drug candidate in the field of oral cancer prevention.
• Bio-Convert's drug delivery system is designed to minimize systemic absorption, potentially reducing side effects.
• Nordicus has secured commitments from its shareholders to capitalize Bio-Convert until the completion of Phase I trials.

Negatives

• The 12,000,000 shares issued by Nordicus are restricted and have not been registered under the Securities Act of 1933, which may limit their immediate liquidity.
• The transaction is an all-stock deal, which means no cash was received by the sellers of Bio-Convert.
• The success of Bio-Convert's drug is dependent on the outcome of clinical trials, which are subject to risks and uncertainties.

Risks

• The success of Bio-Convert's drug is subject to the outcome of clinical trials.
• Market acceptance of Bio-Convert's products and services is not guaranteed.
• Competition from existing or new products may impact the success of Bio-Convert.
• The company's future revenue, expenses, and capital requirements are subject to estimates and may vary.
• Changes in government regulations could affect the company's operations.

Future Outlook

The company plans to conduct a pilot efficacy study in patients with oral leukoplakia and is focused on advancing the development of its pharmaceutical drug for the treatment of oral leukoplakia and the prevention of oral cancer formation.

Management Comments

• Nordicus Partners Corporation is focused on providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market.
• Bio-Convert is aiming to revolutionize the treatment of oral leukoplakia by minimizing or removing oral leukoplakia lesions, that further reduces the risk of patients developing oral cancer from it.

Industry Context

This acquisition reflects a trend of pharmaceutical companies acquiring smaller biotech firms to expand their drug pipelines and address unmet medical needs. The focus on oral cancer prevention aligns with growing concerns about cancer incidence and the need for innovative treatments.

Comparison to Industry Standards

• The acquisition of a clinical-stage biopharmaceutical company by a financial consulting firm is not a typical transaction, but it reflects a strategy of diversification and expansion into the life sciences sector.
• The all-stock transaction is a common method for acquisitions in the biotech industry, especially for companies with limited cash reserves.
• The valuation of Bio-Convert was based on a third-party valuation by Cigno M&A, which is a standard practice in M&A transactions.
• The focus on oral leukoplakia and oral cancer prevention is a niche area within the broader oncology market, with companies like Bristol Myers Squibb and Merck also having oncology programs, but not specifically focused on oral leukoplakia.

Stakeholder Impact

• Shareholders of Nordicus may see potential long-term value from the acquisition.
• Employees of Bio-Convert will become part of Nordicus.
• Patients with oral leukoplakia may benefit from the development of new treatments.
• Suppliers and partners of Bio-Convert will now be associated with Nordicus.

Next Steps

• Bio-Convert plans to conduct a pilot efficacy study in patients with oral leukoplakia.
• Nordicus will continue to support Bio-Convert's development efforts.
• Nordicus will integrate Bio-Convert into its operations.

Key Dates

Keywords

acquisition, biopharmaceutical, oral leukoplakia, oral cancer, stock purchase, clinical-stage, Nordicus Partners Corporation, Bio-Convert ApS, restricted shares